Texas Medication Algorithm Project, phase 3 (TMAP-3)

Clinical results for patients with a history of mania

Trisha Suppes, A. John Rush, Ellen B. Dennehy, M. Lynn Crismon, T. Michael Kashner, Marcia G. Toprac, Thomas J. Carmody, E. Sherwood Brown, Melanie M. Biggs, Kathy Shores-Wilson, Bradley P. Witte, Madhukar H. Trivedi, Alexander L. Miller, Kenneth Z. Altshuler, Steven P. Shon

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background: The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served in public mental health centers. This report presents clinical outcomes in patients with a history of mania (BD), including bipolar I and schizoaffective disorder, bipolar type, during 12 months of treatment beginning March 1998 and ending with the final active patient visit in April 2000. Method: Patients were diagnosed with bipolar I disorder or schizoaffective disorder, bipolar type, according to DSM-IV criteria. ALGO was comprised of a medication algorithm and manual to guide treatment decisions. Physicians and clinical coordinators received training and expert consultation throughout the project. ALGO also provided a disorder-specific patient and family education package. TAU clinics had no exposure to the medication algorithms. Quarterly outcome evaluations were obtained by independent raters. Hierarchical linear modeling, based on a declining effects model, was used to assess clinical outcome of ALGO versus TAU. Results: ALGO and TAU patients showed significant initial decreases in symptoms (p = .03 and p < .001, respectively) measured by the 24-item Brief Psychiatric Rating Scale (BPRS-24) at the 3-month assessment interval, with significantly greater effects for the ALGO group. Limited catch-up by TAU was observed over the remaining 3 quarters. Differences were also observed in measures of mania and psychosis but not in depression, side-effect burden, or functioning. Conclusion: For patients with a history of mania, relative to TAU, the ALGO intervention package was associated with greater initial and sustained improvement on the primary clinical outcome measure, the BPRS-24, and the secondary outcome measure, the Clinician-Administered Rating Scale for Mania (CARS-M). Further research is planned to clarify which elements of the ALGO package contributed to this between-group difference.

Original languageEnglish (US)
Pages (from-to)370-382
Number of pages13
JournalJournal of Clinical Psychiatry
Volume64
Issue number4
StatePublished - Apr 1 2003

Fingerprint

Bipolar Disorder
Therapeutics
Psychotic Disorders
Outcome Assessment (Health Care)
Brief Psychiatric Rating Scale
Patient Education
Diagnostic and Statistical Manual of Mental Disorders
Mental Health

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Suppes, T., Rush, A. J., Dennehy, E. B., Crismon, M. L., Kashner, T. M., Toprac, M. G., ... Shon, S. P. (2003). Texas Medication Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania. Journal of Clinical Psychiatry, 64(4), 370-382.

Texas Medication Algorithm Project, phase 3 (TMAP-3) : Clinical results for patients with a history of mania. / Suppes, Trisha; Rush, A. John; Dennehy, Ellen B.; Crismon, M. Lynn; Kashner, T. Michael; Toprac, Marcia G.; Carmody, Thomas J.; Brown, E. Sherwood; Biggs, Melanie M.; Shores-Wilson, Kathy; Witte, Bradley P.; Trivedi, Madhukar H.; Miller, Alexander L.; Altshuler, Kenneth Z.; Shon, Steven P.

In: Journal of Clinical Psychiatry, Vol. 64, No. 4, 01.04.2003, p. 370-382.

Research output: Contribution to journalArticle

Suppes T, Rush AJ, Dennehy EB, Crismon ML, Kashner TM, Toprac MG et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania. Journal of Clinical Psychiatry. 2003 Apr 1;64(4):370-382.
Suppes, Trisha ; Rush, A. John ; Dennehy, Ellen B. ; Crismon, M. Lynn ; Kashner, T. Michael ; Toprac, Marcia G. ; Carmody, Thomas J. ; Brown, E. Sherwood ; Biggs, Melanie M. ; Shores-Wilson, Kathy ; Witte, Bradley P. ; Trivedi, Madhukar H. ; Miller, Alexander L. ; Altshuler, Kenneth Z. ; Shon, Steven P. / Texas Medication Algorithm Project, phase 3 (TMAP-3) : Clinical results for patients with a history of mania. In: Journal of Clinical Psychiatry. 2003 ; Vol. 64, No. 4. pp. 370-382.
@article{3ace9d5032904afd9cfba9e343a6f860,
title = "Texas Medication Algorithm Project, phase 3 (TMAP-3): Clinical results for patients with a history of mania",
abstract = "Background: The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served in public mental health centers. This report presents clinical outcomes in patients with a history of mania (BD), including bipolar I and schizoaffective disorder, bipolar type, during 12 months of treatment beginning March 1998 and ending with the final active patient visit in April 2000. Method: Patients were diagnosed with bipolar I disorder or schizoaffective disorder, bipolar type, according to DSM-IV criteria. ALGO was comprised of a medication algorithm and manual to guide treatment decisions. Physicians and clinical coordinators received training and expert consultation throughout the project. ALGO also provided a disorder-specific patient and family education package. TAU clinics had no exposure to the medication algorithms. Quarterly outcome evaluations were obtained by independent raters. Hierarchical linear modeling, based on a declining effects model, was used to assess clinical outcome of ALGO versus TAU. Results: ALGO and TAU patients showed significant initial decreases in symptoms (p = .03 and p < .001, respectively) measured by the 24-item Brief Psychiatric Rating Scale (BPRS-24) at the 3-month assessment interval, with significantly greater effects for the ALGO group. Limited catch-up by TAU was observed over the remaining 3 quarters. Differences were also observed in measures of mania and psychosis but not in depression, side-effect burden, or functioning. Conclusion: For patients with a history of mania, relative to TAU, the ALGO intervention package was associated with greater initial and sustained improvement on the primary clinical outcome measure, the BPRS-24, and the secondary outcome measure, the Clinician-Administered Rating Scale for Mania (CARS-M). Further research is planned to clarify which elements of the ALGO package contributed to this between-group difference.",
author = "Trisha Suppes and Rush, {A. John} and Dennehy, {Ellen B.} and Crismon, {M. Lynn} and Kashner, {T. Michael} and Toprac, {Marcia G.} and Carmody, {Thomas J.} and Brown, {E. Sherwood} and Biggs, {Melanie M.} and Kathy Shores-Wilson and Witte, {Bradley P.} and Trivedi, {Madhukar H.} and Miller, {Alexander L.} and Altshuler, {Kenneth Z.} and Shon, {Steven P.}",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "64",
pages = "370--382",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "4",

}

TY - JOUR

T1 - Texas Medication Algorithm Project, phase 3 (TMAP-3)

T2 - Clinical results for patients with a history of mania

AU - Suppes, Trisha

AU - Rush, A. John

AU - Dennehy, Ellen B.

AU - Crismon, M. Lynn

AU - Kashner, T. Michael

AU - Toprac, Marcia G.

AU - Carmody, Thomas J.

AU - Brown, E. Sherwood

AU - Biggs, Melanie M.

AU - Shores-Wilson, Kathy

AU - Witte, Bradley P.

AU - Trivedi, Madhukar H.

AU - Miller, Alexander L.

AU - Altshuler, Kenneth Z.

AU - Shon, Steven P.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Background: The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served in public mental health centers. This report presents clinical outcomes in patients with a history of mania (BD), including bipolar I and schizoaffective disorder, bipolar type, during 12 months of treatment beginning March 1998 and ending with the final active patient visit in April 2000. Method: Patients were diagnosed with bipolar I disorder or schizoaffective disorder, bipolar type, according to DSM-IV criteria. ALGO was comprised of a medication algorithm and manual to guide treatment decisions. Physicians and clinical coordinators received training and expert consultation throughout the project. ALGO also provided a disorder-specific patient and family education package. TAU clinics had no exposure to the medication algorithms. Quarterly outcome evaluations were obtained by independent raters. Hierarchical linear modeling, based on a declining effects model, was used to assess clinical outcome of ALGO versus TAU. Results: ALGO and TAU patients showed significant initial decreases in symptoms (p = .03 and p < .001, respectively) measured by the 24-item Brief Psychiatric Rating Scale (BPRS-24) at the 3-month assessment interval, with significantly greater effects for the ALGO group. Limited catch-up by TAU was observed over the remaining 3 quarters. Differences were also observed in measures of mania and psychosis but not in depression, side-effect burden, or functioning. Conclusion: For patients with a history of mania, relative to TAU, the ALGO intervention package was associated with greater initial and sustained improvement on the primary clinical outcome measure, the BPRS-24, and the secondary outcome measure, the Clinician-Administered Rating Scale for Mania (CARS-M). Further research is planned to clarify which elements of the ALGO package contributed to this between-group difference.

AB - Background: The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served in public mental health centers. This report presents clinical outcomes in patients with a history of mania (BD), including bipolar I and schizoaffective disorder, bipolar type, during 12 months of treatment beginning March 1998 and ending with the final active patient visit in April 2000. Method: Patients were diagnosed with bipolar I disorder or schizoaffective disorder, bipolar type, according to DSM-IV criteria. ALGO was comprised of a medication algorithm and manual to guide treatment decisions. Physicians and clinical coordinators received training and expert consultation throughout the project. ALGO also provided a disorder-specific patient and family education package. TAU clinics had no exposure to the medication algorithms. Quarterly outcome evaluations were obtained by independent raters. Hierarchical linear modeling, based on a declining effects model, was used to assess clinical outcome of ALGO versus TAU. Results: ALGO and TAU patients showed significant initial decreases in symptoms (p = .03 and p < .001, respectively) measured by the 24-item Brief Psychiatric Rating Scale (BPRS-24) at the 3-month assessment interval, with significantly greater effects for the ALGO group. Limited catch-up by TAU was observed over the remaining 3 quarters. Differences were also observed in measures of mania and psychosis but not in depression, side-effect burden, or functioning. Conclusion: For patients with a history of mania, relative to TAU, the ALGO intervention package was associated with greater initial and sustained improvement on the primary clinical outcome measure, the BPRS-24, and the secondary outcome measure, the Clinician-Administered Rating Scale for Mania (CARS-M). Further research is planned to clarify which elements of the ALGO package contributed to this between-group difference.

UR - http://www.scopus.com/inward/record.url?scp=0038034217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038034217&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 370

EP - 382

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 4

ER -